{"id":"CU23267","slug":"brodalumab-for-treatment-of--CU23267","source":{"id":"CU23267","dataset":"techtransfer","title":"Brodalumab for treatment of immune checkpoint inhibitor-induced adverse events","description_":"<p>This technology repurposes the FDA-approved anti-IL-17RA monoclonal antibody Brodalumab for the treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy.</p>\r\r<h2>Unmet Need: Targeted treatment for immune checkpoint inhibitor-associated toxicities</h2>\r\r<p>Current management of immune-related adverse events relies largely on corticosteroids and broad immunosuppressive therapies that can compromise anti-tumor immunity, increase infection risk, and limit continued immunotherapy treatment. As immune checkpoint inhibitors become standard of care across multiple cancer types, there is a growing need for more targeted approaches to control irAEs while maintaining cancer-fighting immune activity.</p>\r\r<h2>The Technology: IL-17 inhibition to treat immunotherapy-associated toxicities</h2>\r\r<p>This technology repurposes Brodalumab, an FDA-approved anti-IL-17 receptor A monoclonal antibody, for the treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy. By inhibiting IL-17-mediated inflammation, Brodalumab provides a targeted approach to reducing inflammatory toxicities while preserving anti-tumor immune responses. Potential applications include treatment of checkpoint inhibitor-induced colitis, dermatitis, arthritis, pneumonitis, and other inflammatory complications.</p>\r\r<h2>Applications:</h2>\r\r<ul>\r<li>Management of immune checkpoint inhibitor-induced colitis</li>\r<li>Management of immune checkpoint inhibitor-induced dermatitis and psoriasis-like toxicities</li>\r<li>Management of immune checkpoint inhibitor-induced arthritis and inflammatory complications</li>\r<li>Steroid-sparing treatment for immune-related adverse events (irAEs)</li>\r<li>Enabling continuation of life-saving cancer immunotherapy</li>\r<li>Potential combination strategy with PD-1, PD-L1, and CTLA-4 inhibitors</li>\r</ul>\r\r<h2>Advantages:</h2>\r\r<ul>\r<li>Targets IL-17-driven inflammation associated with multiple irAEs</li>\r<li>May preserves anti-tumor immunity compared to broad immunosuppressive therapies</li>\r<li>Utilizes an FDA-approved drug with established manufacturing, pharmacology, and safety data</li>\r<li>Enables accelerated clinical development through drug repurposing</li>\r<li>May reduce corticosteroid use and associated toxicities</li>\r<li>Applicable across multiple immune checkpoint inhibitor-treated cancers</li>\r</ul>\r\r<h2>Lead Inventor:</h2>\r\r<p><a href=\"https://www.rheumatologyatcolumbia.org/profile/adam-mor-md\">Adam Mor, M.D., Ph.D.</a></p>\r\r<h2>Patent Information:</h2>\r\r<p>Patent Pending(US<a href=\"https://patents.google.com/patent/US20260015428A1/\">20260015428</a>)</p>\r\r<h2>Related Publications:</h2>\r\r<h2>Tech Ventures Reference:</h2>\r\r<ul>\r<li><p>IR CU23267</p></li>\r<li><p>Licensing Contact: <a href=\"mailto:techtransfer@columbia.edu\">Cynthia Lang</a> </p></li>\r</ul>\r","tags":["Arthritis","CTLA-4","Cancer","Cancer immunotherapy","Colitis","Corticosteroid","Dermatitis","Immune system","Immunotherapy","Inflammation","Monoclonal antibody","PD-L1","Pharmacology","Programmed cell death protein 1","T-cell receptor"],"file_number":"CU23267","collections":[],"meta_description":"Repurposes Brodalumab to curb immune checkpoint inhibitor irAEs by IL-17 blockade, preserving anti-tumor immunity.","apriori_judge_output":"{\"scores\":{\"novelty\":3.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":3.0,\"timeliness\":4.0},\"weighted_score\":3.35,\"risks\":[\"Repurposing from an approved drug provides speed but relies on irAE-specific efficacy data.\",\"Potential safety signals in irAEs population may affect risk/benefit.\",\"Competition from other irAE management approaches and corticosteroid-sparing strategies.\",\"Regulatory path may vary by irAE indication across cancers; need robust biomarkers.\"],\"one_sentence_take\":\"Moderate novelty with meaningful potential impact and timely repurposing, but readiness and scalability are limited by irAE-specific efficacy data and regulatory complexity.\"}","inventors":["Adam Mor","Xizi Hu"],"manager":"Cynthia Lang","depts":["Medicine","Rheumatology"],"divs":["Columbia University Medical Center (CUMC)"],"date_released":"2026-06-26"},"highlight":{},"matched_queries":null,"score":0.0}